Volver a Agenda
Session 5: Penetrating the Market
Session Chair(s)
Juliana Marguerite Reed, MS
Executive Director
The Biosimilars Forum, United States
As the number of approved biosimilars in the US marketplace increases, understanding the perspectives and needs of the patient, payer, and prescriber are key requirements to ensure the successful uptake of biosimilars. This session will explore those perspectives and ways to address the needs of these important stakeholders.
Learning Objective : - Provide an overview of where biosimilars started in Europe and where they are today
- Provide an overview of lessons learned and recommendations in Europe
- Provide physician, patient, and payor/PBM perspectives on needs and requirements for the successful uptake of biosimilars.
- Provide an update on the FDA’s efforts to educate stakeholders on biosimilars
Speaker(s)
Speaker
Suzette Kox, MPharm
Medicines for Europe, Belgium
Senior Director International-Biosimilars Medicines Group
Speaker
Angus Worthing, MD
American College of Rheumatology, United States
Chair, Government Affairs Committee
Speaker
Leah Howard, JD
National Psoriasis Foundation, United States
Vice President, Government Relations and Advocacy
Speaker
Chris Davis
Express Scripts, United States
Director, Government Affairs
Speaker
Ms. Sarah Ikenberry
US FDA, United States
Senior Communication Advisor, OTBB, CDER
Speaker
Cheryl Schwartz
Pfizer, Inc., United States
General Manager, US Biosimilars
Speaker
Tânia Teixeira, PharmD
European Medicines Agency, United States
EMA Official at the FDA
¿Tiene una cuenta?